<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bone marrow transplantation is now an accepted form of therapy for many <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e> including <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, genetically determined diseases and malignant diseases, particularly <z:hpo ids='HP_0001909'>leukemia</z:hpo>, and for rescue of patients given intensive chemoradiotherapy for malignant disease </plain></SENT>
<SENT sid="1" pm="."><plain>The donor may be a healthy identical twin, a family member or even an unrelated person </plain></SENT>
<SENT sid="2" pm="."><plain>Selection is made on the basis of human leukocyte antigen tissue typing </plain></SENT>
<SENT sid="3" pm="."><plain>Intensive chemoradiotherapy is used to suppress patients' immune systems to facilitate engraftment and destroy diseased marrow </plain></SENT>
<SENT sid="4" pm="."><plain>Transfusion of platelets, erythrocytes and granulocytes (or <z:hpo ids='HP_0000001'>all</z:hpo> of these), antibiotic coverage and protection from <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> are necessary during the pancytopenic period </plain></SENT>
<SENT sid="5" pm="."><plain>Use of a Hickman catheter facilitates maintenance of adequate nutritional intake and provides easy access for drawing blood and intravenous administration </plain></SENT>
<SENT sid="6" pm="."><plain>Survival rates vary considerably depending on a patient's disease, clinical state and age </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> transplanted early in the course of their disease have a survival rate of approximately 80% </plain></SENT>
<SENT sid="8" pm="."><plain>Patients with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> are usually transplanted in a second or subsequent remission and have a survival rate of 25% to 40% </plain></SENT>
<SENT sid="9" pm="."><plain>Patients with <z:hpo ids='HP_0011009'>acute</z:hpo> nonlymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> in remission have survivals ranging from 45% to 70% </plain></SENT>
<SENT sid="10" pm="."><plain>More than 200 patients in the <z:hpo ids='HP_0011010'>chronic</z:hpo> phase of <z:hpo ids='HP_0011010'>chronic</z:hpo> granulocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> have been transplanted with survival ranging from 50% to 70% </plain></SENT>
<SENT sid="11" pm="."><plain>Complications of marrow transplantation include marrow graft rejection, <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e>, immunologic insufficiency and the possibility of recurrence of the <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>The risk of <z:hpo ids='HP_0011420'>death</z:hpo> from these complications must be balanced against the possibility of cure </plain></SENT>
</text></document>